Tumor necrosis factor-α-secreting CD16+ antigen presenting cells are effectively removed by granulocytapheresis in ulcerative colitis patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 12, 2010, Pages 1869-1875

  Sanchez Garcia, Joaquin ^a   Serrano López, Juana ^a   García Sanchez, Valle ^a   Alvarez Rivas, Miguel A ^a   Jimenez Moreno, Rosario ^a   Pérez Seoane, Carlos ^a   Herrera Arroyo, Concepcion ^a   Serrano, Josefina ^a   De Dios, Juan F ^a   Torres Gomez, Antonio ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Antigen presenting cells; Tumor necrosis factor ; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CD16 ANTIGEN; INTERLEUKIN 10; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; GRANULOCYTAPHERESIS; HUMAN; LEUKAPHERESIS; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 78649550175     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06377.x     Document Type: Article

References (33)

1. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 2007; 117: 514-21.
2. Young Y, Abreu MT. Advances in the pathogenesis of inflammatory bowel disease. Curr. Gastroenterol. Rep. 2006; 8: 470-7.
3. Rogler G. Update in inflammatory bowel disease pathogenesis. Curr. Opin. Gastroenterol. 2004; 20: 311-17.
4. Bell SJ, Rigby R, English N et al. Migration and maturation of human colonic dendritic cells. J. Immunol. 2001; 166: 4958-67.
5. Niess JH, Reinecker HC. Dendritic cells: the commanders-in-chief of mucosal immune defenses. Curr. Opin. Gastroenterol. 2006; 22: 354-60.
6. Kelsall BL, Leon F. Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease. Immunol. Rev. 2005; 206: 132-48.
7. Stagg AJ, Hart AL, Knight SC et al. The dendritic cells: its role in intestinal inflammation and relationship with gut bacteria. Gut 2003; 52: 1522-29.
8. MacDonald KPA, Munster DJ, Clark GJ et al. Characterization of human blood dendritic cell subsets. Blood 2002; 100: 4512-20.
9. Piccioloi D, Tavarini S, Borgogni E et al. Functional specialization of human circulating CD16 and CD1c myeloid dendritic cell subsets. Blood 2007; 109: 5371-9.
10. - dendritic cells. Clin. Immunol. 2001; 100: 325-38.
11. Ziegler-Heitbrock L. The CD14+CD16+ blood monocytes: their role in infection and inflammation. J. Leuk. Biol. 2007; 81: 1-9.
12. Belge KU, Dayyani F, Horelt A et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J. Immunol. 2002; 168: 3536-42.
13. Krutzik SR, Tan B, Li H et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat. Med. 2005; 11: 653-60.
14. Randolph GJ, Sanchez-Schmitz G, Liebman RM et al. The CD16(+)(FcγRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J. Exp. Med. 2002; 196: 517-27.
15. De Baey A, Mende I, Baretton G et al. A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J. Immunol. 2003; 170: 5089-94.
16. Hart AL, Al-Hassi HO, Rigby RJ et al. Characteristics of intestinal dendritic cell in inflammatory bowel disease. Gastroenterology 2005; 129: 50-65.
17. Te Velde AA, Van Kooyk Y, Braat H et al. Increased expression of DC-SIGN+IL-12+IL18+ and CD83+IL-12-IL-18- dendritic cell population in the colonic mucosa of patients with Crohn's disease. Eur. J. Immunol. 2003; 33: 143-51.
18. Vuckovic S, Florin TH, Khalil D et al. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases. Am. J. Gastroenterol. 2001; 96: 2946-56.
19. Ikeda Y, Akbar F, Matsui H et al. Characterization of antigen-presenting dendritic cells in the peripheral blood and colonic mucosa of patients with ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 2001; 13: 841-50.
20. Baumgart DC, Metzke D, Schmitz J et al. Patients with active inflammatory bowel disease lack immature peripheral blood plasmocytoid and myeloid dendritic cells. Gut 2005; 54: 228-36.
21. Naganuma M, Funakoshi S, Sakaruba A et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or dependent ulcerative colitis. Inflamm. Bowel. Dis. 2004; 10: 251-7.
22. Hanai H, Iida T, Yamada M et al. Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. World J. Gastroenterol. 2006; 12: 3393-99.
23. Giampaolo B, Giuseppe P, Michele B et al. Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: our experience with a prospective study. World J. Gastroenterol. 2006; 12: 2201-4.
24. pos dendritic precursors cells. Br. J. Haematol. 2004; 124: 636-44.
25. Bueno C, Rodriguez-Caballero A, García-Montero A et al. A new method for detecting TNF-α-secreting cells using direct-immunofluoresecence surface membrane stainings. J. Immunol. Methods 2002; 264: 77-87.
26. Kellar KL, Douglass JP. Multiplexed microsphere-based flow cytometric immunoassays for human cytokines. J. Immunol. Methods 2003; 279: 277-85.
27. Mende I, Hoffmann P, Wolf A et al. Highly efficient antigen targeting to M-DC8+ dendritic cells via FcgammaRIII/CD16-specific antibody conjugates. Int. Immunol. 2005; 17: 539-47.
28. Bajtay Z, Csomor E, Sandor N et al. Expression and role of Fc and complement receptors on human dendritic cells. Immunol. Lett. 2006; 104: 46-52.
29. Waitz G, Petremann S, Liebe S et al. Reduction of dendritic cells by granulocyte and monocyte adsorption apheresis in patients with ulcerative colitis. Dig. Dis. Sci. 2008; 53: 2507-15.
30. + monocytes in leukocytapheresis therapy for ulcerative colitis. Inflamm. Bowel. Dis. 2007; 13: 284-90.
31. Hanai H, Iida T, Takeuchi K et al. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2008; 103: 1210-16.
32. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005; 353: 2462-76.
33. Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Granulocytapheresis versus methylprednisolone in patients with ulcerative colitis: 12-month follow-up. J. Gastroenterol. Hepatol. 2008; 23: 1678-82.